The catabolism of intact, reactive centre-cleaved and proteinase- complexed C1 inhibitor in the guinea pig

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 191-197

  Malek, R ^a   Aulak, K S ^a   Davis III, A E ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

complement; protein catabolism; serpins

Indexed keywords

BLOOD CLOTTING FACTOR 12; KALLIKREIN;

AMINO ACID SEQUENCE; ANGIONEUROTIC EDEMA; ANIMAL CELL; ARTICLE; CATABOLISM; COMPLEMENT DEFICIENCY; DATA ANALYSIS; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; GUINEA PIG; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEQUENCE ANALYSIS;

EID: 0030057113     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-714.x     Document Type: Article

References (34)

1. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Ann Rev Immunol 1988; 6:595-628.
2. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Int Med 1976; 84:580-93.
3. 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28:8951-66.
4. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Ann Rev Biochem 1980; 49:593-626.
5. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52:655-709.
6. Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257:3243-8.
7. Laurell M, Stenflo J, Carlson TH. Turnover of *I-Protein C inhibitor and *I-αi-antitrypsin and their complexes with activated protein C. Blood 1990; 76:2290-5.
8. 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochem Biophys Acta 1988; 967:158-62.
9. 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991; 30:1723-30.
10. Pratt CW, Church FC, Pizzo SV. In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. Arch Biochem Biophys 1988; 262:111-7.
11. Matheson NR, van Halbeek H, Travis J. Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions. J Biol Chem 1991; 266:13489-91.
12. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ, Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87:3753-7.
13. Pizzo SV. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med 1989; 87 (Suppl. 3B):10s-14s.
14. 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J Biol Chem 1990; 265:16713-6.
15. 2antiplasmin-protease complexes in mice. Thromb Haem 1982; 48:208-10.
16. de Smet BJGL, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native proteinase-complexed, and proteolytically inactivated Cl-inhibitor in rats. Blood 1993; 81:56-61.
17. 1-antitrypsin-protease complexes. J Biol Chem 1991; 266:11282-8.
18. Pilatte Y, Hammer CH, Frank MM, Fries LF. A new simplified procedure for Cl inhibitor purification. A novel use for jacalinagarose. J Immunol Methods 1989; 120:37-43.
19. Salvesen GS, Catanese JJ, Kress LF, Travis J. Primary structure of the reactive site of human Cl inhibitor. J Biol Chem 1985; 260:2432-6.
20. Markwell MAK. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Analyt Biochem 1982; 125:427-31.
21. 131I labeled plasma proteins. Phys Med Biol 1957; 2:36-53.
22. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. Behavior in vivo of normal and dysfunctional Cl inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71:1041-6.
23. Bleeker WK, van der Plas J, Agterberg J, Rigter G, Bakker JC. Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2 formylpyridoxal 5́-phosphate. J Lab Clin Med 1986; 108:448-54.
24. Berger Jr H, Kirstein CG, Orthner CL. Pharmacokinetics of activated protein C in guinea pigs. Blood 1991; 77:2174-84.
25. Comp PC. Life-span of plasma coagulation factors. In: Williams WJ, Beutler E, Erslav AJ, Lichtman MA, eds. Hematology. New York: McGraw-Hill, 1990:1290-4.
26. Gonias SL, Balber AE, Hubbard WJ, Pizzo SV. Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. Biochem J 1983; 209:99-105.
27. 1-proteinase inhibitor. Arch Biochem Biophys 1986; 248:587-96.
28. 1AT. J Biol Chem 1993; 268:1886-93.
29. Stein PE, Leslie AGW, Finch JT, Turnell WG, McLaughlin PJ, Carrell RW. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 1990; 347:99-102.
30. Mottonen J, Strand A, Symersky J et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355:270-3.
31. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJM, Grottenhuis PDJ, Hol WGJ. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Struct Biol 1994; 1:48-54.
32. Wei A, Rubin H, Cooperman BS, Christianson DW. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Struct Biol 1994; 1:251-8.
33. Patston PA, Medcalf RL, Kourteva Y, Schapira M. Cl inhibitorserine proteinase complexes and the biosynthesis of Cl-inhibitor by HepG2 and U937 cells. Blood 1993; 82:3371-9.
34. Morton PA, Owensby DA, Wun TC, Billadello JJ, Schwartz AL. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem 1990; 265:14093-9.